drugset
drugset / Trial / NCT05463432

A Study of HR19024 in Subjects With Advanced Solid Tumor

NCT05463432 ↗

Phase 1 Completed 71 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety，tolerability，pharmacokinetic characteristics and preliminary efficacy of HR19024 injection in the treatment of advanced solid tumor

Timeline

Start
2022-08-10
Primary completion
2024-10-22
Completion
2024-10-22

Drugs

EvaluationDrugModalityDoseRoute
Subject HR19024 Unknown — Intravenous

Indications

No indication recorded.